In the past six months, companies have seen a significant influx of AI-powered phishing, as cyberattackers progress from small campaigns to 1-to-1 personalized attacks.
North Korea’s Lazarus Targets macOS Users via ClickFix
Lazarus continues leveraging ClickFix for initial access and data theft, in this case, against Mac-centric organizations and their high-value leaders.
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Medicines Agency’s …
Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
→ Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the news …
FDA declines to approve AbbVie’s Botox follow-up
AbbVie’s bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Older adults’ acceptability and perceived barriers to digital health tools integrating nutrition and physical activity: a focus group study
IntroductionThe rapid ageing of the population presents significant public health challenges, particularly in countries with high life expectancy such as Italy. Although nutrition and physical activity are key determinants of healthy ageing, many older adults do not meet recommended guidelines. Mobile health (mHealth) technologies may support healthy behaviors; however, evidence on older adults’ perspectives remains […]
Older adults’ acceptability and perceived barriers to digital health tools integrating nutrition and physical activity: a focus group study
IntroductionThe rapid ageing of the population presents significant public health challenges, particularly in countries with high life expectancy such as Italy. Although nutrition and physical activity are key determinants of healthy ageing, many older adults do not meet recommended guidelines. Mobile health (mHealth) technologies may support healthy behaviors; however, evidence on older adults’ perspectives remains […]
Locally-deployed vs. cloud-based AI in healthcare: evaluating DeepSeek-R1:8b, DeepSeek-R1, and ChatGPT o3-mini-high for complex medical diagnostics
Reasoning large language models are increasingly considered for healthcare-related artificial intelligence applications, but their practical value depends not only on diagnostic accuracy, but also on responsiveness and operational reliability. In this study, we benchmarked six model settings on 1,000 questions from the MedQA dataset: DeepSeek-R1, its distilled 8-billion-parameter local variant DeepSeek-R1:8b, ChatGPT o3-mini-high, and their […]
Locally-deployed vs. cloud-based AI in healthcare: evaluating DeepSeek-R1:8b, DeepSeek-R1, and ChatGPT o3-mini-high for complex medical diagnostics
Reasoning large language models are increasingly considered for healthcare-related artificial intelligence applications, but their practical value depends not only on diagnostic accuracy, but also on responsiveness and operational reliability. In this study, we benchmarked six model settings on 1,000 questions from the MedQA dataset: DeepSeek-R1, its distilled 8-billion-parameter local variant DeepSeek-R1:8b, ChatGPT o3-mini-high, and their […]
Travere’s launchpad positions Filspari for fast rise toward blockbuster sales: analyst
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its new indication and power the franchise to peak sales of $3.1 billion, Guggenheim Securities analysts predicted in a note to investors.
Daiichi Sankyo postpones annual results, stock dips
Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year that ended …
FDA clears first genetic hearing loss gene therapy
Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.